Q2 FY27 revenue up 42.7%, PAT up 71.4%, guidance raised
ACUTAAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Q2 FY27 revenue rose 42.7% year on year to Rs 4,369 million, while PAT rose 71.4% to Rs 1,231 million and PAT margin reached 28.2%. H1 revenue grew 49.3% to Rs 7,666 million and PAT grew 71.0% to Rs 1,981 million. Pharmaceutical intermediates led growth, while specialty chemicals were softer. The South Korea plant opened ahead of schedule, and FY27 revenue growth guidance was raised to around 30% with a 38% to 40% EBITDA margin target.
Strong profit growth, wider margins and raised guidance support positive earnings momentum. Risks include new-plant execution and softer specialty chemicals.